Literature DB >> 34895527

High-dose budesonide for early COVID-19.

Ivan Berezowski1, Jigar Patel2, Mariame Shaw2, Ali Pourmand2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 34895527      PMCID： PMC8660056          DOI： 10.1016/S0140-6736(21)02441-7

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  1 in total

1.  Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial.

Authors:  Ly-Mee Yu; Mona Bafadhel; Jienchi Dorward; Gail Hayward; Benjamin R Saville; Oghenekome Gbinigie; Oliver Van Hecke; Emma Ogburn; Philip H Evans; Nicholas P B Thomas; Mahendra G Patel; Duncan Richards; Nicholas Berry; Michelle A Detry; Christina Saunders; Mark Fitzgerald; Victoria Harris; Milensu Shanyinde; Simon de Lusignan; Monique I Andersson; Peter J Barnes; Richard E K Russell; Dan V Nicolau; Sanjay Ramakrishnan; F D Richard Hobbs; Christopher C Butler
Journal:  Lancet       Date:  2021-08-10       Impact factor: 79.321
  1 in total
  1 in total

Review 1.  An overview of current drugs and prophylactic vaccines for coronavirus disease 2019 (COVID-19).

Authors:  Armina Alagheband Bahrami; Ali Azargoonjahromi; Samin Sadraei; Aryan Aarabi; Zahra Payandeh; Masoumeh Rajabibazl
Journal:  Cell Mol Biol Lett       Date:  2022-05-13       Impact factor: 8.702
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.